| breast cancer - triple negative | |||
| mBC - TNBC - L1 - all population | mBC-Triple negative (TNBC) - 2nd Line (L2) | mBC - TNBC - L2 - all population | |
| poly ADP-ribose polymerase (PARP) inhibitor | |||
| olaparib | OlympiAD | ||
| talazoparib | EMBRACA | ||
| veliparib plus paclitaxel plus carboplatin | BrighTNess ... BrighTNess ... | ||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
